Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials
Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity July 29, 2025 Francesco Bevione, Maria Carla Lacidogna, Raffaele Lavalle et al. 3 citations
Abstract Background Fluoxetine remains the only pharmacological treatment approved for Bulimia Nervosa, and no other drugs have been approved for eating disorders (EDs). The rationale for exploring psilocybin as a treatment for EDs is compelling, both from biological and psychological perspectives. Moreover, its safety profile in healthy individuals appears favorable. This systematic review...
DOI: 10.1007/s40519-025-01771-y (opens in new tab)
Full text (opens in new tab)
Psilocybin
Eating disorders
Anorexia nervosa
Clinical trial
+6